Boundless Bio Inc. Common Stock (BOLD)

About BOLD

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

28

Website

boundlessbio.com/

Fundamentals

1-day range

$2.8$2.86

Market cap

$63.80M

P/E (trailing)

—

P/E (forward)

-2.89

EPS (trailing)

$-2.50

Dividend yield

—

Beta

0.67

Avg. volume

1.30M

Forecasts

1 analyst ratings

Boundless Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BOLD

  Boundless Bio Inc. Common Stock

  $2.83

  ▼ 1.05%
  Market cap $63.80MP/E —
  $0.9612$3.16
• PMVP

  PMV Pharmaceuticals Inc. Common Stock

  $1.22

  ▼ 1.61%
  Market cap $62.93MP/E —
  $1.02$1.88
• PLRX

  Pliant Therapeutics Inc. Common Stock

  $1.11

  ▼ 3.48%
  Market cap $65.02MP/E —
  $1.02$1.95
• XLO

  Xilio Therapeutics Inc. Common Stock

  $9

  ▼ 0.22%
  Market cap $60.95MP/E —
  $6.47$12.74
• MNOV

  Medicinova Inc Common Stock

  $1.44

  ▲ 1.05%
  Market cap $66.94MP/E —
  $1.17$1.96
• RNTX

  Rein Therapeutics Inc. Common Stock

  $0.7621

  ▼ 2.67%
  Market cap $67.45MP/E —
  $0.694$2.18
• CING

  Cingulate Inc. Common Stock

  $5.32

  ▼ 2.21%
  Market cap $68.02MP/E —
  $3.16$11.89

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate
  benzinga · 8/10/2026
• Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate
  Benzinga · 8/10/2026

• TANG KEVIN · August 26, 2026 · Sale

  18.3K @ $2.97
• TANG KEVIN · July 21, 2026 · Buy

  3.0K @ $2.44
• TANG KEVIN · July 20, 2026 · Buy

  1.6K @ $2.44
• TANG KEVIN · July 17, 2026 · Buy

  265 @ $2.44
• TANG KEVIN · July 16, 2026 · Buy

  18.5K @ $2.44
• TANG KEVIN · July 15, 2026 · Buy

  1.6K @ $2.44
• TANG KEVIN · July 14, 2026 · Buy

  43.9K @ $2.43
• TANG KEVIN · July 13, 2026 · Buy

  48.2K @ $2.42
• TANG KEVIN · July 10, 2026 · Buy

  43.4K @ $2.43
• TANG KEVIN · July 9, 2026 · Buy

  7 @ $2.48
• TANG KEVIN · July 8, 2026 · Buy

  14.3K @ $2.46
• TANG KEVIN · July 7, 2026 · Buy

  15.8K @ $2.48
• TANG KEVIN · July 6, 2026 · Buy

  27.1K @ $2.49
• TANG KEVIN · July 2, 2026 · Buy

  9.8K @ $2.49
• ARCH Venture Fund IX, L.P. · July 1, 2026 · Option Exercise

  16.0K @ $1.03

Institutional Ownership

March 31, 2026

Total shares held

8.42M

Total value held

$9.14M

Institutional holders

33